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Abstract
With the advent of induced pluripotent stem cell (iPSC) technology, it is now feasible to generate
iPSCs with a defined genotype or disease state. When coupled with direct differentiation of
defined lineage, such as hepatic endoderm (HE). iPSC would revolutionise the way we study
human liver biology and generate efficient “off the shelf” models of human liver disease.
Here we show the `proof of concept' that iPSC lines representing both male and female sexes and
two ethnic origins can be differentiated to HE at efficiencies of between 70–90%, using a method
mimicking a physiological condition. iPSC-derived HE exhibited hepatic morphology, and
expressed the hepatic markers, Albumin and E-Cadherin as assessed by immuno-histochemistry.
They also expressed alpha fetal protein (AFP), HNF4a, and a metabolic marker, Cyp7A1,
demonstrating a definitive endodermal lineage differentiation. Furthermore, iPSC-derived
hepatocytes produced and secreted the plasma proteins, fibrinogen, fibronectin, transthyretin
(TTR) and AFP, an essential feature for functional HE. Additionally iPSC-derived HE supported
both CYP1A2 and 3A4 metabolism, which is essential for drug and toxicology testing.
Conclusion—This work is first to demonstrate the efficient generation of hepatic endodermal
lineage from human iPSC that exhibits key attributes of hepatocytes, and the potential application
of iPSC-derived HE in studying human liver biology. In particular, iPSC from individuals
representing highly polymorphic variants in metabolic genes and different ethnic groups will
provide pharmaceutical development and toxicology studies a unique opportunity to revolutionise
predictive drug toxicology assays and allow the creation of in vitro hepatic disease models.
INTRODUCTORY STATEMENT
Human iPSCs are reprogrammed mature somatic fibroblasts which represent a pluripotent
cell population able to generate all primary cell types in vitro [1–3]. The ability to derive
iPSCs from an indefinite range of genotypes makes them an attractive resource on which to
model liver function reflecting the complexity of polygenic influences on metabolism in
vitro. Another facet of iPSC technology is the ability to study the impact of gene
polymorphisms in a native chromatin setting and model with precision, gene interactions.
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Therefore iPSC-derived models hold great potential to develop a detailed understanding of
human liver disease and metabolism including drug toxicity (for a review see Dalgetty et al
[4]). Any methods which might streamline and standardize the process of drug and
toxicology testing, which currently relies on primary human hepatocytes, would represent a
significant development. Therefore an iPSC resource representative of polymorphic variants
and ethnic groups; unhindered by quality and supply, would revolutionise predictive drug
toxicology assays and impact on drug attrition.
Presently primary human hepatocytes (PHHs) are the golden standard cell type used in
predictive drug toxicology. Unfortunately PHHs are a scare, heterogeneous and expensive
resource which function only short term in vitro. The generation of HE from iPSCs has the
potential to fulfil the major challenge to acquire the reliable and clonal source of functional
human hepatocyte cells for biotechnology purposes. To date efficient models of deriving
hepatic endoderm from iPSCs have not been described or developed. Capitalising on our
recent investigations that hESCs can be stimulated to form hepatic endoderm [5], we have
developed a parallel methodology for iPSCs, here we describe the generation of functional
hepatic endoderm from multiple human iPSCs lines that can potentially model human drug
metabolism.
EXPERIMENTAL PROCEDURES
Generation of human iPS cells
iPS cells from diabetic North American Indian (JDM-iPS1) and female Caucasian (PGP9-
iPS1) were reported previously [6–7]. 1×105 fibroblasts of normal male Caucasian (ATCC:
CRL-2465) were plated in one well of a six-well plate and infected with four individual
retrovirus each containing a single reprogramming factor, Oct4, Sox2, Klf4 and c-MYC,
was used at a MOI of 10 [1]. After 3 days of infection, cells were split into 10cm plates pre-
seeded with irradiated mouse embryonic fibroblasts (MEFs) and cultured under human ES
culture medium conditions until colonies appeared. Colonies were picked, replated onto
irradiated MEFs and expanded for characterization.
Cell Culture and Differentiation
iPS cell colonies were maintained in hES medium (80% KO/DMEM, 20% KO Serum
Replacement, 10ng/ml bFGF, 1 mM L-glutamine, 100mM non-essential amino acids,
100uM 2-mercaptoethanol, 50U/ml penicillin, and 50mg/ml streptomycin (Invitrogen)) on
an irradiated mouse embryonic feeder layer (CF-1, VHbio). Before HE differentiation,
iPSCs were cultured on Matrigel™ (BD Biosciences). iPSCs were differentiated to
hepatocyte like cells using Activin A and Wnt3a (R&D systems) on Matrigel™ (BD
biosciences). Although the differentiation protocol was similar to that of Hay et al [5], one
major modification was required in order to generate human hepatic endoderm from human
iPSCs. In brief, after iPSCs were passaged onto matrigel and cultured in MEF-CM until a
confluence of 50–70% was attained, MEF-CM was then replaced with RPMI/B27 and iPSCs
treated with Activin A and Wnt3a for 3 days and required a further 2 day incubation in
Activin A (100ng/ml) alone before hepatic endoderm was specified using established
conditions as follows: Cells were cultured in SR/DMSO (KO-DMEM containing 20% serum
replacement (SR), 1mM glutamine, 1% non-essential amino acids, 0.1mM β-
mercaptoethanol and 1% DMSO). The final maturation Step involved culturing the cells in
L-15 medium which was supplemented with 8.3% fetal calf serum, 8.3% tryptose phosphate
broth, 10μM Hydrocortisone 21-hemisuccinate, 1μM insulin, 2mM glutamine and
supplemented with 10ng/ml Hepatocyte growth factor and 20ng/ml Oncostatin M [5]. For
further information see supplementary Figure 2.
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Flow Cytometry
Cells were resuspended at 1× 107 cells/ml in FACS-PBS (PBS supplemented with 0.1%
BSA and 0.1% sodium azide). Aliquots of 1 × 106 cells were incubated for 40 minutes at
4°C with optimum concentration (determined by titration), of primary antibody to SSEA-1
(mouse IgM), SSEA-4 (mouse IgG3) (DHSB, Iowa, USA), TRA-1-60 (anti-mouse IgM,
Chemicon) and EpCAM-APC (CD326, Biolegend). Cells were washed twice to remove
unbound antibody and resuspended in 100μl FACS-PBS. Binding of primary antibody was
detected using optimum concentration (determined by titration) of appropriate isotype
specific fluorochrome labeled secondary antibody or Avidin: anti-mouse IgM – PE and anti-
rat IgM-PE and anti-mouse IgG3-FITC (Jackson Labs) and Streptavidin (Caltag
Medsystems). After incubation for 40m at 4°C cells were washed twice and finally re-
suspended in 250μl. Unstained cells and cells labeled with secondary antibody alone were
included as controls. Dead and apoptotic cells and debris were excluded from analysis using
an electronic `live gate on forward scatter and side scatter parameters. Data for up to 25,000
`live' events were acquired for each sample using a FACSCaliber cytometer equipped with a
488nm and 633nm lasers and analysed using CellQuest software (Becton Dickinson).
RT-PCR
RNA was isolated using RNeasy kit (Qiagen, West Sussex, U.K., http://www1.qiagen.com)
following manufacturer's instruction and DNA was removed by the treatment with DNase
(Qiagen). cDNA was synthesised using 2 μg total RNA with reverse transcriptase (Roche
Diagnostics) in a 20–25 μl volume. Polymerase chain reaction (PCR) was carried out as
previously described [1,5]. Primer sequences and PCR conditions are provided in
supplemental online data Table 1. qPCR carried out as Hay et al. [5].
Assay for Teratoma Formation
For teratoma formation, cells were harvested, washed once with DMEM/F12 and mixed
with Matrigel (BD Biosciences) and collagen [8–9]. 1×106 cells were injected
intramuscularly into immune-compromised NSG mice. Teratomas formed within 6–8 weeks
and paraffin sections were stained with Masson Trichromatic for all histological
determinations.
Immunocytochemistry
Cells were fixed with chilled Methanol (−20 °C) for 10 minutes, washed with PBS, and
blocked with 10% goat serum and 0.02%–0.1% Triton X-100 for 1 hour. The cells were then
incubated with primary antibody at the appropriate dilution at 4°C overnight. Secondary
antibody was applied for 30 minutes after washing with PBS. The cells were finally
mounted with Mowiol (Calbiochem) and then visualized and captured using a Leica
DMIRB.
ELISA
ELISAs were carried out as previously described [5].
Cytochrome p450 Assay
CYP1A2 and CYP3A4 activity was assessed using the pGlo kit (Cat nos. V8771, V8901
Promega) according to manufacturer's instruction for non-lytic CYP450 activity estimation.
CYP activities are expressed as relative light units (RLU/ml) per of media, normalised
against percentage of hepatocyte like cells.
Sullivan et al. Page 3
Hepatology. Author manuscript; available in PMC 2011 January 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
RESULTS
We have previously demonstrated a successfully generation of iPSCs that are capable of self
renewal and differentiation by retroviral transduction of four transcription factors [1]. As
iPSCs colonies appeared, they where manually disaggregated and plated onto a feeder layer
and sequentially passaged (Supplementary Figure 1 and [6–7]). The derived iPSC lines were
characterised using a number of stem cell criteria: cell morphology, stem cell gene
expression, stem cell surface expression of SSEA 3, 4 and Tra 1–60 and absence of SSEA1
and teratoma formation in vivo (Supplementary Figure 1 and [6–7]). By applying the
method we had used for differentiating, we attempted to generate hepatic endodermal
lineage from human iPSCs. We initially focused our efforts on iPS cell line derived from
normal adult Caucasian male, NMF-iPS6 (Figure 1Aa). NMF-iPS6 were differentiated
towards hepatic endoderm via physiologically relevant conditions; treatment with Wnt3a/
Activin A, Activin A followed by DMSO and a final maturation step with hepatic growth
factor and Oncostatin M [5] (Figure 1Ab). Differentiation of iPS cells into hepatic endoderm
was associated with a dramatic change in cellular morphology similar to hepatocyte
differentiation. Hepatic phenotype was assessed by the albumin production (Figure 1Ac) and
E-Cadherin (Figure 1Ad) confirmed by immunofluorescence. We observed an efficiency of
hepatic endoderm generation of between 70–90%, as assessed by albumin positive cells
(Figure 1Ac). HE derived from the male Caucasian iPSCs (NMF-iPS6) expressed a number
of key hepatic transcripts as assessed by RT-PCR, namely AFP, HNF4. In addition, we
observed the expression of the endodermal markers, Sox17 and CXCR4 [10] at day 5 in the
procedure (data not shown) and CYP7A1 (Figures 1 and 2) which demonstrates both a
definitive endoderm origin and importantly is not derived from yolk sac [11]. Additionally,
upon differentiation, pluripotent marker OCT4 which expressed in iPS cells became down-
regulated (Figure 1B). One of the immediate potential applications of iPSC-derived HE is
the human drug toxicity assessment, and therefore we investigated the expression of two key
adult cytochrome p450's, CYP1A2 and CYP3A4. Both enzymes were induced in HE cells
compared with undifferentiated iPS cells, ~6 fold increase in CYP1A2 and ~6000 fold
increase in CYP3A4 levels (Figure 1C).
In addition to the male Caucasian NMF-iPS cell line, we also applied HE differentiation
protocol to iPS cells derived from diabetic North American Indian (JDM-iPS1) and female
Caucasian (PGP9f-iPS1) (Figure 2Aab). Both iPS cell lines differentiated into HE with
similar efficiencies as male Caucasian NMF-iPS6 cell line. HE differentiation was assessed
by cell morphology and albumin staining (Figure 2A cde). When we analysed hepatic gene
expression in the iPSC-derived HE, both lines exhibited similar gene expression patterns as
observed from NMF-iPS6 cells, indicating hepatic identity (Figure 2B).
Although iPSC-derived HE expressed a number of liver genes, we were also keen to assess
their liver specific function in culture. An important functional marker for HE is the
production and export of serum proteins. We assessed iPSC-HE production of these key
serum proteins and measured their levels by ELISA. In all lines tested, we detected
substantial amounts of AFP, TTR, Fibronectin and Fibrinogen at levels equivalent to those
reported for HE derived from hESCs [5].
In order to further functionally validate, iPSC-derived HE were assessed for their metabolic
ability. The cytochrome P450 enzymes are critical in drug metabolism, and CYP1A2 and
CYP3A4 are the key enzymes. The function of these P450 components were examined and
importantly all lines exhibited CYP1A2 and CYP3A4 activity as assessed by the generation
of a luminescent metabolite (Figure 4). CYP1A2 metabolism was similar between lines
PGP9f-iPS1 and NMF-iPS6 but was higher in line JDM-iPS1, while we observed only slight
variation with CYP3A4 metabolism in all 3 lines tested.
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DISCUSSION
Here we demonstrate for the first time the derivation of HE from human iPSC of both sexes
and two ethnicities. The iPSC-derived HE was functionally equivalent to hESC-derived HE
and interestingly all iPSC lines tested so far showed higher efficientcy to form functional
HE. The generic ability of iPSCs to form HE in response to our model [5] has not been
observed with hESC in deriving efficient levels of HE. Therefore one could speculate that
this is due to the consistent manner in which the iPSCs were reprogrammed may play an
important role in their developmental potential. It also suggests that iPSC may prove a more
valuable and uniform starting material for derivation of HE, than from human embryonic
stem cells which show dramatic line to line variability in susceptibility to individual lineage
differentiation.
Such a resource has the ability to revolutionise the manner in which we define drug
metabolism, model liver disease and human liver development. Because iPSC-derived HE
can be differentiated ex-vivo, the unlimited supply of ethically and genetically diverse HE
models can be obtained. This will become a powerful resource allowing the study of ethnic/
polymorphic variation on xenobiotic metabolism involving poor metabolisers (e.g. CYP2C9/
Warfarin) and disease genotypes (e.g. alpha 1-antitrypsin). In addition, the ability to model
liver development in vitro will allow the development of novel biomarkers for both disease
and the identification of stage specific makers during the differentiation process [12].
Identification and reprogramming of human fibroblasts displaying metabolically different
features for key polymorphisms, an iPSC library could be developed. Presently the ability to
model the human liver and disease using hESCs or PHHs is limited by the number of stem
cell lines available and the ability to produce functional HE from individual ESC lines.
Therefore, by applying iPSC HE technology we predict these will by-pass the issues
associated with hESCs and PHHs.
In conclusion: Our studies provide a proof of concept that multiple iPSCs lines can be
efficiently differentiated to functioning HE. In addition provides a novel approach that
overcomes the current limitations associated with PHHs and hESCs. We predict that this
technology will be applicable to iPSC lines derived from healthy and diseased patients from
different ethnic backgrounds allowing the creation of a library. The development of such a
resource is essential in the identification and testing of new medicines and the modelling of
disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Derivation of hepatic endoderm from iPSCs
(Aa) Phase contrast microscropy demonstrating the typical iPSC colony morphology and
(Ab) iPSC-derived hepatic endoderm (HE) following 14 days in the differentiation
procedure (Magnification x20). (Ac) iPSC-derived HE stains positive for albumin at day 14
in the differentiation procedure. The numbers represent the efficiency of the procedure +/−
SE. (Ad) iPSC-derived HE stains positive for E-Cadherin at day 14 in the differentiation
procedure (B) RT-PCR gene expression of iPSCs and iPSC-derived hepatic endoderm.
iPSC-derived hepatic endoderm on (lane 1) express the markers AFP, CYP7A1 and HNF4
alpha, but not OCT-4. iPSCs strongly express OCT4. Potentially due to spontaneous
differentiation found in iPSC culture. PCR reactions were controlled using a –RT control
(lane 4) and details of primers and cycles can be found in the supplementary methods
section (C) CYP1A2 and CYP3A4.
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Figure 2. Derivation of HE from 2 other iPSC lines
(Aa,b) Phase contrast microscropy demonstrating the typical iPSC HE morphology
following 14 days in the differentiation procedure (Magnification x20). (Ac,d) IPSC-derived
HE stains positive for albumin at day 14 in the differentiation procedure. The numbers
represent the efficiency of the procedure +/− SE. (B) RT-PCR gene expression of iPSCs and
iPSC-derived hepatic endoderm. iPSC-derived hepatic endoderm on (lane 1) express the
markers AFP, and HNF4 alpha, but not OCT-4. iPSCs strongly express OCT4. Potentially
due to spontaneous differentiation found in iPSC culture. PCR reactions were controlled
using a –RT control (-RT) and details of primers and cycles can be found in the
supplementary methods section
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Figure 3. iPSC-derived hepatic endoderm produces hepatic specific serum proteins
iPSC-derived hepatic endoderm was maintained in 1ml of hepatocyte culture medium for 24
hours. The following morning culture supernatants were harvested and serum protein
production measured by ELISA and quoted as ng/ml of tissue culture medium per 24 hours.
Note background has been removed from the presented data. Each line is represented as a
different coloured bar: JDM-iPS1 is presented by the first bar in all graphs, PGP9ff-iPS1 is
repsresented by the middle bar in each graph and NMF-iPS6 is represented by the last bar in
each graph. In all lines the serum protein tested was detected. fibrinogen and transthyretin
(TTR), fibronectin and alpha-fetoprotein (AFP) (n=6).
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Figure 4. iPSC-derived hepatic endoderm displays cytochrome P450 metabolism
iPSC-derived hepatic endoderm were incubated with hepatocyte culture medium
supplemented with 50 μM of CYP3A4 or CYP1A2 pGlo TM substrates (Promega) as per
manufacturers instructions. 4 hours post-treatment 50 μl of culture medium was removed
and read on a luminometer (POLARstar optima). CYP1A2 and CYP3A4 activity is
expressed as relative light units (R.L.U.)/ml of tissue culture medium. (n=6). CYP1A2
activity was similar on cells maintained on both ECMs. Luciferase activity is expressed as
relative light units (R.L.U.)/ml of tissue culture media. JDM-iPS1 is presented by the first
bar in all graphs, PGP9f-iPS1 is represented by the middle bar in each graph and NMF-iPS6
is represented by the last bar in each graph.
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